How This Company’s Rare Plant Expertise Could Potentially Disrupt a Multi-Billion Dollar Market (1)

See why now could be the best time to start your research on InMed Pharmaceuticals Inc. (Nasdaq: INM).

How Rare Canna-bi-noids Are Transforming the Pharmaceutical Landscape…(1)

Image Source (2)
Canna-bi-noids, the chemical compounds found in the canna-bis plant, have long intrigued scientists and medical researchers. While the well-known canna-bi-noids like canna-bi-diol (C-B-D) and tetrahydrocanna-bi-nol (T-H-C) have stolen the limelight, there exists a vast world of over 200 lesser-known canna-bi-noids, each with unique properties and potential therapeutic benefits. Among these underexplored compounds are canna-bi-gerol (CBG), canna-binol (CBN), tetrahydrocannabivarin (T-H-CV), and many more. What sets these rare canna-bi-noids apart is their remarkable medical potential without the mind-altering effects associated with T-H-C. (1)

Unveiling the ECS Connection (1)
Central to understanding the impact of rare canna-bi-noids is grasping the role of the endocanna-bi-noid system (ECS) within our bodies. Comprising receptors, enzymes, and endocanna-bi-noids, the ECS regulates vital functions such as sleep, mood, appetite, memory, and fertility. When canna-bi-noids interact with the ECS, they trigger a range of beneficial effects, promoting balance and harmony within the body.

Endocanna-bi-noids, naturally produced by the body, facilitate proper internal function. Receptors for these endocanna-bi-noids are distributed throughout the body, serving as signaling points for ECS activity. Enzymes come into play by breaking down endocanna-bi-noids once their role is fulfilled, maintaining the ECS’s dynamic equilibrium.

A Healthcare Transformation in the Making (1)
Emerging studies have illuminated the potential of canna-bi-noids in addressing a wide array of medical conditions. Several clinical trials on canna-bi-noids have yielded promising data on their therapeutic benefits. For instance, C-B-D has been approved for epilepsy and is being studied for other disorders such as anxiety. These findings are just the tip of the iceberg, hinting at the vast potential canna-bi-noids hold in improving health and well-being.

The potential impact of rare canna-bi-noids on the medical industry is immense. As these compounds become more accessible and affordable, they will unlock new avenues for medical treatment and wellness. Rare canna-bi-noids like CBG/CBGA, CBN/CBNA, T-H-CV/T-H-CVA, and T-H-CA have shown compelling evidence of their health benefits.
Among the pioneering companies in this transformative field is InMed Pharmaceuticals Inc. (Nasdaq: INM).

As the pharmaceutical industry undergoes this profound shift driven by rare canna-bi-noids, InMed Pharmaceuticals Inc. (Nasdaq: INM) stands as one of the little-known yet promising companies to keep a close eye on.

With its commitment to research, development, and innovation in canna-bi-noid-based pharmaceuticals, InMed Pharmaceuticals Inc. (Nasdaq: INM) may play a significant role in shaping the future of healthcare.

Keep reading to see why InMed Pharmaceuticals Inc. (Nasdaq: INM) needs to be at the top of your daily watch list…

7 Reasons Why InMed Pharmaceuticals Inc. (Nasdaq: INM) Could Be Poised For Significant Upside Potential Ahead of 2024…

1. Active Chart

InMed Pharmaceuticals Inc. (Nasdaq: INM) has demonstrated the potential for significant upside potential with a 52-week range of $.2913 - $3.03. Not that any returns to previous highs are certain, but the potential for 940% upside suggests a strong reason to begin your research on this company after their shares fell from their 52-week high on 1/4/2023 to a recent 52-week low bounce on 11/20/2023. (6)

2. Groundbreaking Potential:

With its innovative approach to Alzheimer's disease treatment through INM-901 and its pioneering work in the treatment of Age-Related Macular Degeneration with INM-089, InMed Pharmaceuticals Inc. (Nasdaq: INM) presents groundbreaking potential across multiple therapeutic fronts. INM-901, in particular, has demonstrated unique pharmacological effects in preclinical studies, including neuroprotection and enhanced neuronal function. Exploring the research on INM-901 and INM-089 may reveal the prospect of substantial breakthroughs in the fields of Alzheimer's and AMD treatments. (17)(20)

3. Revenue-Generating Subsidiary

Having a revenue-generating subsidiary, InMed Pharmaceuticals Inc. (Nasdaq: INM) enjoys a unique advantage among pharmaceutical companies. This subsidiary provides a financial foundation for enhancing the company's ability to fund ongoing research and development activities without relying solely on external financing. (5)(11)

4. Expertise in Canna-bi-noid Manufacturing

With the growing interest in canna-bi-noids for various medical and market sectors, InMed Pharmaceuticals Inc. (Nasdaq: INM) has significant expertise in developing innovative manufacturing approaches for producing canna-bi-noids. This know-how positions InMed well to produce canna-bi-noids for various market sectors. (11)

5. Significant Valuation Gap

Despite its promising pipeline and revenue-generating subsidiary, InMed Pharmaceuticals Inc. (Nasdaq: INM)’s market capitalization remains below $5 million as of 11/17/2023, according to the company’s corporate presentation. (22) This valuation gap suggests that the company could be trading well below its true intrinsic value, making it an intriguing research opportunity for those seeking undervalued assets.

6. Listed on Nasdaq Exchange:

Being listed on a major exchange brings increased visibility, liquidity, and credibility, offering distinct advantages for a company. InMed Pharmaceuticals Inc. (Nasdaq: INM)'s presence on the Nasdaq exchange sets it apart from many cann-a-bis-related companies, which often trade on smaller or less-regulated exchanges. (13)

7. Rare Canna-bi-noid Production

Through its wholly owned subsidiary, BayMedica, InMed Pharmaceuticals Inc. (Nasdaq: INM) produces highly pure rare canna-bi-noids such as d9-T-H-CV, CBC, C-B-DV, and CBT for the consumer health and wellness industry. As the demand for these unique canna-bi-noids grows, InMed could be well-positioned to supply these valuable compounds to an expanding market. (11)

Could InMed Pharmaceuticals Inc. (Nasdaq: INM) Have Over 940%in Potential Upside? (6)

Chart Source (8)
InMed Pharmaceuticals Inc. (Nasdaq: INM) is demonstrating the potential for significant upside potential with a 52-week range of $.2913 – $3.03. Not that any returns to previous highs are certain, but the potential for 940% upside suggests a strong reason to begin your research on this company after their shares fell from their 52-week high on 1/4/2023 and more and recently bounced off their 52-week low on 11/20/2023. (6)

According to StockCharts.com, InMed Pharmaceuticals Inc. (Nasdaq: INM) is currently displaying significant upside potential to the following moving averages as of 11/28/2023:(8)
A return to any previous highs isn’t certain, but it’s important to note the potential upside from current levels.

Despite its promising pipeline and revenue-generating subsidiary, InMed Pharmaceuticals Inc. (Nasdaq: INM) is considered a “nano-cap” stock because its market capitalization remains below $5 million according to the company’s corporate presentation. (22).
Image Source (11)
This valuation gap suggests that the company could be trading well below its true intrinsic value, making it an intriguing research opportunity.

In general, nano-cap companies have market capitalizations of less than $50 million. (14) Because nano-cap stocks are significantly smaller than mid-cap or large-cap companies, they have a higher potential to change valuation quickly. (15)

Nano-cap stocks may be overlooked by the market, as they often receive little attention from analysts and institutions. This can provide excellent research opportunities for individuals who are seeking to discover hidden gems. These small and often little-known companies may bring major improvements to existing products and services as well as introducing new products, using innovation to accelerate growth. (16)

This is why things could get very interesting and why you need to start your research on InMed Pharmaceuticals Inc. (Nasdaq: INM).

Unveiling InMed Pharmaceuticals Inc. (Nasdaq: INM): Pioneering Rare Canna-bi-noid Advancements (11)

Image Source (11)
In the ever-evolving landscape of pharmaceuticals, InMed Pharmaceuticals Inc. (Nasdaq: INM) has emerged as a trailblazer. This innovative company is at the forefront of dr-ug discovery and development, specializing in the realm of rare canna-bi-noids. (11)

A Pure-Play Rare Canna-bi-noid Company (11)
InMed Pharmaceuticals Inc. (Nasdaq: INM) is a pure-play rare canna-bi-noid company, dedicated to unraveling the therapeutic potential of canna-bi-noids. With a focus on pharmaceutical research and development (R&D), InMed’s endeavors encompass a wide range of pharmaceutical programs targeting various medical conditions. Their specialized areas of interest include dermatological, ocular, and neurodegenerative diseases.

Rare Canna-bi-noid Expertise Across Several Areas (11)
Canna-bi-noid Drug Development Programs (11)
Image Source (11)
Naturally-Occurring Canna-bi-noids: INM-755 (Epidermolysis Bullosa)
Image Source (11)
Naturally-Occurring Canna-bi-noids: INM-088 (Glaucoma)
Image Source (11)

Canna-bi-noid Analogs: INM-900 Series (Neurodegenerative Diseases)

Image Source (11)
With a diverse portfolio of pharmaceutical programs, rare canna-bi-noid expertise, and a dedication to forging strategic partnerships, the company is poised to unlock the full potential of canna-bi-noid medicines.

As the world witnesses the ongoing evolution of canna-bi-noid-based therapies, InMed’s pioneering work promises new horizons for patients and offers a glimpse into the future of pharmaceuticals, where rare canna-bi-noids play a pivotal role in addressing unmet medical needs.

SUBSCRIBE TO OUR NEWSLETTER FOR MUST READ REPORTS & NEWS.

Getting the Right News Before Everyone Else Does, is FREE…

InMed Pharmaceuticals Inc. (Nasdaq: INM): Pioneering New Hope in Alzheimer's Disease Treatment with INM-901(17)

Alzheimer’s disease is a devastating neurodegenerative condition that affects millions of individuals worldwide, and it has long been one of the most challenging diseases to tackle in the field of medicine. However, there is a glimmer of hope on the horizon in the form of InMed Pharmaceuticals Inc. (Nasdaq: INM) and their groundbreaking Alzheimer’s disease drug candidate, INM-901.

InMed Pharmaceuticals recently made waves in the medical and pharmaceutical communities by announcing the selection of INM-901 as a lead candidate for the treatment of Alzheimer’s disease. This promising development comes on the heels of a series of successful preclinical proof-of-concept studies that have shown INM-901 to have unique and potent pharmacological effects in the context of Alzheimer’s disease.

The Promise of INM-901 (17)
One of the standout features of INM-901 is its ability to target multiple biological pathways associated with Alzheimer’s disease. Moreover, it has demonstrated the capacity to improve neuronal function by extending neurite length, which is a key indicator of enhanced neuronal performance.

In addition to these encouraging in vitro findings, INM-901 has also shown remarkable results in in vivo preclinical studies conducted in a validated Alzheimer’s disease treatment model. When compared to placebo-treated Alzheimer’s disease groups, those treated with INM-901 exhibited a trend toward improvement in various crucial areas:(17)

– Cognitive Function and Memory
– Locomotor Activity
– Anxiety-Based Behavior
– Sound Awareness


These findings represent a significant breakthrough in Alzheimer’s disease research and offer newfound hope for individuals and families affected by this debilitating condition.

A Rigorous Candidate Selection Process (17)
The journey to discovering INM-901 began with InMed’s exploration of neuroprotective effects in their ocular disease/glaucoma development program (INM-088). This initial research led to the screening of multiple canna-bi-noids against various non-ocular neuron models, including those in the brain. Among these canna-bi-noids, one emerged as a standout candidate for protection against neurodegenerative diseases of the brain.

InMed’s research team further refined this candidate by developing several analogs to maximize its potential effects. Subsequent screening in Alzheimer’s disease assays identified two analogs that were then advanced to in vivo preclinical testing using a well-established Alzheimer’s proof-of-concept model. Based on the promising results of these preclinical tests, INM-901 emerged as the final candidate for continued pharmaceutical research and development.

Addressing the Limitations of Current Treatments (17)
The current landscape of Alzheimer’s disease treatments primarily focuses on managing symptoms related to memory and cognitive function through the reduction of beta-amyloid plaques. While these medications can slow the rate of cognitive decline, they do not reverse the disease’s effects or address the underlying neurodegeneration. Additionally, these treatments are associated with significant side effects, including brain inflammation and bleeding, necessitating regular brain scans.

In contrast, INM-901 offers the potential for disease-modifying effects, making it a promising candidate for Alzheimer’s disease treatment. By targeting multiple receptor systems and possessing the ability to cross the blood-brain barrier, INM-901 represents a multi-pronged approach to treating this complex neurological disorder.

Progress and Future Prospects (17)
InMed’s recent breakthrough in Alzheimer’s disease research is a testament to the dedication and innovation of their scientific team. Their progress includes filing international patents that acknowledge the potential use of rare canna-bi-noids and analogs, like INM-901, in the treatment of various neurodegenerative diseases, including Alzheimer’s.

A presentation at the Canadian Neuroscience Meeting showcased the ability of a specific rare canna-bi-noid to reduce amyloid toxicity and tau protein expression while promoting neuronal cell growth and neuritogenesis markers. These findings align with the critical targets in the potential treatment of neurodegenerative diseases like Alzheimer’s.

Dr. Eric Hsu, InMed’s Senior Vice President of Preclinical Research and Development, summed up the excitement surrounding INM-901, stating, “The most recent studies of INM-901 demonstrate promising disease-modifying effects in an Alzheimer’s disease treatment model. We are optimistic that the next stage of studies will continue to show how this canna-bi-noid analog can improve neuronal function, a potential breakthrough in Alzheimer’s treatment.” (17)

Alzheimer’s disease remains a significant unmet medical need, and INM-901 may hold the key to transforming the lives of those affected by this devastating condition. As InMed Pharmaceuticals continues to advance their research and development efforts, there is newfound hope that a breakthrough treatment for Alzheimer’s disease is on the horizon, offering solace to patients and their families.

InMed Pharmaceuticals Inc. (Nasdaq: INM): A Year of Achievements, Aims For Strong Start to 2024… (5)(18)

Image Source (10)
InMed Pharmaceuticals Inc. (Nasdaq: INM) has been at the forefront of innovation in the pharmaceutical industry, making significant strides in the research, development, manufacturing, and commercialization of rare canna-bi-noids and canna-bi-noid analogs. As we look back on the achievements of 2023 and the promising start to 2024, it’s clear that InMed is poised for a bright future. (5)(18)

A Recap of the Remarkable Fiscal Year 2023 (5)
The year 2023 was a remarkable one for InMed Pharmaceuticals Inc. (Nasdaq: INM), marked by impressive financial performance, clinical trial advancements, and an expanding pharmaceutical pipeline. Here are the key highlights:

Exceptional Financial Performance (5)
One of the standout achievements of 2023 was InMed’s exceptional financial performance. The company reported total sales for its subsidiary, BayMedica, of rare canna-bi-noids reaching an impressive $4.1 million for the fiscal year. This represented a remarkable 280% increase compared to the previous fiscal year, underscoring InMed’s ability to meet the growing demand for rare compounds effectively.

As of June 30, 2023, InMed Pharmaceuticals Inc. (Nasdaq: INM) boasted a robust financial position, with $9.0 million in cash, cash equivalents, and short-term investments. This financial strength provided the company with a solid foundation to support its ongoing operations and meet its capital expenditure requirements. (5)

Importantly, the fiscal year 2023 witnessed a significant reduction in InMed Pharmaceuticals Inc. (Nasdaq: INM)’s net loss, which amounted to $7.9 million, compared to a net loss of $18.6 million in the previous year. This substantial improvement signaled the company’s ability to generate growing revenue streams and its commitment to effective cost management. (5)

Advancements in Clinical Trials and Pharmaceutical Pipeline(5) Throughout 2023, InMed Pharmaceuticals Inc. (Nasdaq: INM) was actively involved in clinical trials, achieving noteworthy milestones. Here are the key highlights:

Epidermolysis Bullosa (EB) Trial: InMed successfully completed its Phase 2 clinical trial for the treatment of Epidermolysis Bullosa (EB). Although the trial did not yield statistically significant results, it demonstrated clinically meaningful anti-itch activity in a majority of participants, with 27.8% experiencing superior results compared to the control cream. This outcome prompted InMed to explore strategic partnership opportunities for the further development of INM-755 in EB treatment and other anti-itch indications with broader commercial potential.

Ocular Programs: InMed Pharmaceuticals Inc. (Nasdaq: INM) made substantial progress in its ocular programs, particularly in the treatment of glaucoma. The company actively conducted preclinical testing for a CBN-based eye drop formulation, positioning itself to address a significant market need.(5) Furthermore, InMed expanded its research to explore the potential of certain canna-bi-noids in neuroprotection of the eye and extended its focus to include the treatment of Age-Related Macular Degeneration (AMD).

Neurodegenerative Diseases Program: The most exciting development of 2023 was the launch of the INM-900 series program, dedicated to addressing neurodegenerative diseases such as Alzheimer’s, Huntington’s, and Parkinson’s. InMed Pharmaceuticals Inc. (Nasdaq: INM)’s research uncovered the potential of canna-bi-noids in providing neuroprotection, opening up promising avenues for the treatment of brain-related diseases. The company identified two canna-bi-noid analogs (INM-900 series) showing tremendous promise in the treatment of neurodegenerative diseases, setting the stage for further preclinical research.

First Quarter Fiscal 2024 Financial Results and Business Update (18)
With the successes of 2023 as a strong foundation, InMed Pharmaceuticals Inc. (Nasdaq: INM) is off to an impressive start in 2024. The company recently unveiled its first-quarter fiscal 2024 financial results, highlighting key developments and financial stability that bode well for the future. (18)

Financial Highlights (18)
In the first quarter of fiscal 2024, InMed recorded a net loss of $2.5 million, a notable improvement compared to the net loss of $3.5 million reported for the same quarter in the previous year. This demonstrates the company’s commitment to financial prudence and cost management.

Research and development and patents expenses for the first quarter of fiscal 2024 totaled $1.3 million, slightly down from $1.4 million during the same period in the previous year. However, the company anticipates increased research and development expenses in calendar year 2024 as it advances its preclinical work in INM-901 and conducts IND enabling studies in ocular disease.

General and administrative expenses amounted to $1.3 million for the first quarter of fiscal 2024, down from $1.6 million in the same period of the previous year. This decrease was mainly driven by changes in the InMed segment, including lower office and admin fees, accounting and legal fees, stock-based compensation expenses, regulatory fees, and consulting fees.

At the close of the quarter on September 30, 2023, InMed Pharmaceuticals held cash, cash equivalents, and short-term investments totaling $6.7 million. Following the close of the quarter, on October 26, 2023, the company successfully completed a $5.2 million financing, further enhancing its financial position.

The prudent management of expenses and strategic financing have provided InMed Pharmaceuticals with added financial stability, ensuring it can continue to advance its pharmaceutical pipeline candidates and meet its planned operating expenses and capital expenditure requirements into the third quarter of calendar year 2024.

Business Update (18)
InMed Pharmaceuticals has not only showcased its financial prowess but has also provided significant updates on its business operations:

Pharmaceutical Development Programs: InMed Pharmaceuticals continues to make significant progress in its neurodegenerative diseases program, particularly with INM-901, offering hope in Alzheimer’s treatment. The company is conducting advanced preclinical studies, covering critical aspects such as drug distribution, metabolism, pharmacokinetics, and pharmaceutical drug development activities like manufacturing and formulation.

In the dermatology program, INM-755 has displayed promising results in a Phase 2 clinical trial for the treatment of symptoms related to epidermolysis bullosa (EB). InMed is actively exploring partnership opportunities to advance INM-755.

BayMedica Commercial Subsidiary: BayMedica, the company’s commercial subsidiary, continues to experience robust year-over-year revenue growth. While there was a quarter-over-quarter decrease in revenue of 61%, mainly attributed to distributor order patterns and product mix, the company anticipates sustained growth as the market expands and brands innovate by incorporating new canna-bi-noid ingredients into their product offerings. (18)

InMed Pharmaceuticals is actively working to lower manufacturing costs, improve margins over time, and align production and inventory levels with sales demand and forecasts. (18)

Looking Ahead (18)
InMed Pharmaceuticals Inc. (Nasdaq: INM) has made significant strides in its pharmaceutical development programs, achieving promising results with INM-901 in Alzheimer’s disease and INM-755 in dermatology. Additionally, its commercial subsidiary, BayMedica, is experiencing remarkable revenue growth, positioning the company well for the future.

As the company moves forward into 2024, InMed Pharmaceuticals remains committed to innovation and breakthroughs in rare canna-bi-noids and canna-bi-noid analogs, benefiting both patients and industry stakeholders alike. The company’s financial stability, clinical advancements, and expanding pharmaceutical pipeline make it a key player in shaping the future of pharmaceuticals.

BayMedica's Strong Commercial Growth (5)

Image Source 22
InMed Pharmaceuticals Inc. (Nasdaq: INM)’s subsidiary, BayMedica, has been experiencing robust revenue growth, with sales of non-intoxicating rare canna-bi-noids in the health and wellness sector reaching $4.1 million for fiscal year 2023. This represents a remarkable 280% increase compared to the previous year. Importantly, BayMedica achieved three consecutive quarters of substantial revenue growth, with Q2, Q3, and Q4 of 2023 seeing impressive increases of 46%, 100%, and 123%, respectively. Although Q1 fiscal 2024 saw a drop in revenue it still represented a 181% increase over the same period in the previous year.

While revenue fluctuations are expected in this emerging market, BayMedica’s recent performance underscores its potential in the rare canna-bi-noids sector.

To support its growth, BayMedica has optimized and scaled up manufacturing processes, secured additional sources of raw materials, and established downstream purification partnerships. These efforts ensure the consistent supply of high-purity rare canna-bi-noids with minimal batch-to-batch variations.
Image Source (11)

Looking Ahead (5)

InMed Pharmaceuticals Inc. (Nasdaq: INM)’s accomplishments in fiscal year 2023 reflect its commitment to advancing the field of rare canna-bi-noids and canna-bi-noid analogs. With an expanding pharmaceutical pipeline, and a subsidiary making significant inroads in the health and wellness sector, the company is well-positioned for continued growth and innovation.

In the words of Eric A. Adams, InMed’s Chief Executive Officer, “We remain optimistic about the long-term growth potential in the rare canna-bi-noids sector as the business dynamics and commercial opportunities continue to mature.”(5)

Unlocking the Potential of Rare Canna-bi-noids: InMed Pharmaceuticals Inc. (Nasdaq: INM) 11

Image Source 11
InMed Pharmaceuticals Inc. (Nasdaq: INM) has embarked on a pioneering journey in the world of pharmaceuticals, with a primary focus on the research and development of rare canna-bi-noids. Leveraging the inherent therapeutic properties of canna-bi-noids found in the canna-bis plant, InMed is at the forefront of dr-ug development programs aimed at addressing a wide range of medical conditions.

A Diverse Portfolio of Canna-bi-noid Drug Development Programs (11)


InMed Pharmaceuticals Inc. (Nasdaq: INM)’s (11) commitment to advancing the field of canna-bi-noid-based pharmaceuticals is evident through its diverse portfolio of dr-ug development programs. These programs span various phases of research, preclinical, and clinical trials, offering promising solutions to a multitude of health challenges.

Naturally-Occurring Canna-bi-noids: INM-755 (11)
One of InMed Pharmaceuticals Inc. (Nasdaq: INM)’s notable achievements is the development of INM-755, for the treatment of Epidermolysis bullosa (EB). EB is a rare genetic disorder characterized by fragile skin, leading to severe blistering and skin erosions. In a Phase 2 clinical trial, INM-755 demonstrated a positive indication of enhanced anti-itch activity compared to a control cream. While the trial did not yield statistically significant results, the clinically meaningful improvement in anti-itch activity has opened doors for further development. InMed is actively pursuing strategic partnerships to advance the potential of INM-755 in the treatment of EB and other anti-itch indications.

INM’s Ocular Disease Programs (11)
InMed Pharmaceuticals Inc. (Nasdaq: INM)’s  foray into ocular diseases is exemplified by INM-088, targeting glaucoma. Glaucoma is a leading cause of irreversible blindness worldwide, characterized by increased intraocular pressure that can damage the optic nerve. In preclinical studies, INM-088 has showcased promising results, effectively lowering intraocular pressure in the front of the eye. Additionally, it has demonstrated neuroprotection properties in the back of the eye, offering potential benefits in preserving vision.

Exploring Therapeutic Uses with Other R&D
In addition to the highlighted programs, InMed Pharmaceuticals Inc. (Nasdaq: INM) is actively engaged in ongoing research and development (R&D) efforts to screen for therapeutic uses of canna-bi-noids. The company’s commitment to innovation and exploration is a testament to its dedication to harnessing the full potential of these compounds.

Strategic Partnerships: Fueling the Future (11)

As InMed Pharmaceuticals Inc. (Nasdaq: INM) advances its canna-bi-noid dr-ug development programs, strategic partnerships play a pivotal role in shaping the future of these therapies. Collaborations with industry leaders and innovators are poised to accelerate the journey towards bringing these groundbreaking treatments to patients in need.

Latest Development
InMed Pharmaceuticals Inc. (Nasdaq: INM) Expands Its Pipeline with INM-089: A Promising AMD Treatment… (20)
(Image Source 21)
InMed Pharmaceuticals Inc. (Nasdaq: INM) continues to make significant strides in the field of pharmaceutical research and development with the recent announcement of its new ocular pharmaceutical program, INM-089. This program aims to investigate the potential of a canna-bi-nol (CBN) analog in treating Age-Related Macular Degeneration (AMD). The launch of INM-089 represents a significant expansion of InMed’s pipeline and offers hope for patients affected by this debilitating eye condition. (20)

INM-089 and AMD (20)
Age-Related Macular Degeneration is a prevalent cause of vision loss and potential blindness among individuals aged 50 and above. It affects approximately 35% of people aged 75 and older worldwide. AMD primarily targets the central vision and the ability to see fine details, making it a debilitating condition for those affected. There are two primary types of AMD: “dry” AMD, which accounts for roughly 90% of cases and is characterized by geographic atrophy (GA) in the macula, and “wet” AMD, which constitutes around 10% of cases and involves the development of excess vasculature that can lead to rapid blindness. Unfortunately, there is currently no cure for AMD, and the available treatment options aim to slow the disease’s progression.

InMed’s INM-089 program seeks to address this pressing medical need by developing a potential treatment for AMD. Early results from a study conducted in collaboration with canna-bi-noid expert Dr. Mauro Maccarrone at the Università degli Studi dell’Aquila in Italy are promising. The study demonstrated that INM-089 preserved retinal function in an in vivo AMD disease model. Furthermore, treatment with INM-089 improved the thickness of the outer nuclear layer (ONL) of the retina, where photoreceptors are located. The thickness of the ONL is closely correlated with photoreceptor preservation and visual acuity. (20)

Selecting the Right CBN Analog (20)
In the quest to find the most suitable candidate for AMD treatment, InMed Pharmaceuticals screened several CBN analog structures in both in vitro and in vivo models. Among these candidates, a specific CBN analog stood out, outperforming its natural canna-bi-noid counterpart and demonstrating promising effects related to AMD treatment. This discovery represents a significant step forward in the development of potential therapies for AMD, addressing a critical unmet medical need. (20)

The Role of INM-089 in Neuroprotection
One of the key attributes of INM-089 is its potential neuroprotective effect in the retina. By proactively protecting nerve cells at the back of the eye, particularly in the retinal area, INM-089 may preserve retinal function and vision in preclinical models. This neuroprotection is especially relevant in the context of AMD, where the degeneration of retinal cells contributes to vision loss.

InMed’s Scientific Advisor, Dr. Mauro Maccarrone, expressed optimism about the findings, stating, “Early studies show promising neuroprotective effects of INM-089, leading to the preservation of retinal function at the back of the eye. Neuroprotection in AMD remains an unmet medical need, and a new treatment option may help solve this multifactorial disease.” (20)

Expanding InMed’s Ocular Pipeline (20)
INM-089 represents the second ocular pharmaceutical program in InMed’s pipeline, with the first being INM-088, which focuses on glaucoma. This expansion into ocular therapies underscores InMed’s commitment to addressing a wide range of eye-related conditions, from front-of-eye to back-of-eye indications, including AMD.

InMed Pharmaceuticals Inc. (Nasdaq: INM) is making significant strides in the field of pharmaceutical research and development with its new program, INM-089, targeting the treatment of Age-Related Macular Degeneration. The promising results from early studies, including neuroprotective effects and retinal function preservation, provide hope for individuals affected by this debilitating eye condition. InMed’s commitment to expanding its ocular pipeline demonstrates its dedication to addressing unmet medical needs and improving the lives of patients with eye-related conditions. As research and development efforts continue, the potential for a new treatment option for AMD remains a beacon of hope for those living with this challenging disease.

Behind the success of InMed Pharmaceuticals Inc. (Nasdaq: INM) and BayMedica lies a team of experts in the field of canna-bi-noids: (11)

Eric A. Adams, CEO: With over 30 years of experience in global biopharma leadership, Eric Adams leads the company’s strategic vision.

Alexandra Mancini, SVP: Alexandra brings 30+ years of global biopharma R&D experience to the table, overseeing clinical and regulatory affairs. (11)

Michael Woudenberg, COO: Michael’s 20+ years of engineering and manufacturing experience ensure efficient and scalable production. (11)

Eric Hsu, SVP, Preclinical R&D: With 20+ years of scientific leadership in gene transfer technologies, Eric drives preclinical research. (11)

Phil Barr, Senior Consultant: Phil offers strategic planning expertise, having worked with top-tier companies in the pharmaceutical industry. (11)

Colin Clancy, VP, IR & Corp Communications: Colin’s financial and investor relations background ensures transparent communication with stakeholders. (11)
Looking ahead, InMed Pharmaceuticals aims to evaluate commercial partnerships, advance its ocular program, select candidates for its neurodegenerative disease program, and identify and execute strategic partnerships. These initiatives reflect the company’s commitment to driving innovation and making a lasting impact on the pharmaceutical landscape.

As they continue to explore the therapeutic applications of rare canna-bi-noids, they are poised to make further breakthroughs, offering hope to those in need of novel treatments.

How This Company’s Rare Plant Expertise Could Potentially Disrupt a Multi-Billion Dollar Market (1)

See why now could be the best time to start your research on InMed Pharmaceuticals Inc. (Nasdaq: INM).

1. Active Chart

InMed Pharmaceuticals Inc. (Nasdaq: INM) has demonstrated the potential for significant upside potential with a 52-week range of $.2913 - $3.03. Not that any returns to previous highs are certain, but the potential for 940% upside suggests a strong reason to begin your research on this company after their shares fell from their 52-week high on 1/4/2023 to a recent 52-week low bounce on 11/20/2023. (6)

2. Groundbreaking Potential:

With its innovative approach to Alzheimer's disease treatment through INM-901 and its pioneering work in the treatment of Age-Related Macular Degeneration with INM-089, InMed Pharmaceuticals Inc. (Nasdaq: INM) presents groundbreaking potential across multiple therapeutic fronts. INM-901, in particular, has demonstrated unique pharmacological effects in preclinical studies, including neuroprotection and enhanced neuronal function. Exploring the research on INM-901 and INM-089 may reveal the prospect of substantial breakthroughs in the fields of Alzheimer's and AMD treatments. (17)(20)

3. Revenue-Generating Subsidiary

Having a revenue-generating subsidiary, InMed Pharmaceuticals Inc. (Nasdaq: INM) enjoys a unique advantage among pharmaceutical companies. This subsidiary provides a financial foundation for enhancing the company's ability to fund ongoing research and development activities without relying solely on external financing. (5)(11)

4. Expertise in Canna-bi-noid Manufacturing

With the growing interest in canna-bi-noids for various medical and market sectors, InMed Pharmaceuticals Inc. (Nasdaq: INM) has significant expertise in developing innovative manufacturing approaches for producing canna-bi-noids. This know-how positions InMed well to produce canna-bi-noids for various market sectors. (11)

5. Significant Valuation Gap

Despite its promising pipeline and revenue-generating subsidiary, InMed Pharmaceuticals Inc. (Nasdaq: INM)’s market capitalization remains below $5 million as of 11/17/2023, according to the company’s corporate presentation.(22 )This valuation gap suggests that the company could be trading well below its true intrinsic value, making it an intriguing research opportunity for those seeking undervalued assets.

6. Listed on Nasdaq Exchange

Being listed on a major exchange brings increased visibility, liquidity, and credibility, offering distinct advantages for a company. InMed Pharmaceuticals Inc. (Nasdaq: INM)'s presence on the Nasdaq exchange sets it apart from many cann-a-bis-related companies, which often trade on smaller or less-regulated exchanges. (13)

7. Rare Canna-bi-noid Production

Through its wholly owned subsidiary, BayMedica, InMed Pharmaceuticals Inc. (Nasdaq: INM) produces highly pure rare canna-bi-noids such as d9-T-H-CV, CBC, C-B-DV, and CBT for the consumer health and wellness industry. As the demand for these unique canna-bi-noids grows, InMed could be well-positioned to supply these valuable compounds to an expanding market. (11)

Sources:

Source 1: https://tinyurl.com/4jbezm8a

Source 2: https://tinyurl.com/yrvjvctz

Source 3: https://static.seekingalpha.com/uploads/2016/8/8/42544696-14707022875232582_origin.jpg

Source 4: https://tinyurl.com/57det22r

Source 5: https://finance.yahoo.com/news/inmed-pharmaceuticals-reports-full-fiscal-172100106.html

Source 6: https://www.barchart.com/stocks/quotes/INM/price-history/historical

Source 7: https://finviz.com/quote.ashx?t=INM&p=d

Source 8: https://schrts.co/ZuNTmSGx

Source 9: https://www.sofi.com/learn/content/understanding-low-float-stocks/

Source 10: https://www.inmedpharma.com/wp-content/uploads/2023/04/InMed-Wide-logo-Web.png

Source 11: https://www.inmedpharma.com/wp-content/uploads/2023/02/InMed-Corporate-Deck-October-2023.pdf

Source 12: https://www.marketwatch.com/investing/stock/inm?mod=search_symbol

Source 13: https://www.nasdaq.com/solutions/listings/markets/nordics/main-market#:~:text=A%20listing%20on%20the%20Main,the%20company%20and%20its%20business.

Source 14: https://www.investopedia.com/terms/n/nanocap.asp

Source 15:  https://www.benzinga.com/money/best-nano-cap-stocks

Source 16: https://www.globexmarkets.com/financial-terms/n/nano-cap-stock.html

Source 17: https://finance.yahoo.com/news/inmed-pharmaceuticals-inc-inm-901-113000705.html

Source 18: https://finance.yahoo.com/news/inmed-reports-first-quarter-fiscal-130400163.html

Source 19: https://finance.yahoo.com/news/inmed-pharmaceuticals-announces-closing-5-231500164.html

Source 20: https://finance.yahoo.com/news/inmed-expands-pharmaceutical-pipeline-inm-130000663.html

Source 21: https://www.inmedpharma.com/pharmaceutical/inm-089-for-age-related-macular-degeneration/

Source 22: https://www.inmedpharma.com/wp-content/uploads/2023/02/InMed-Corporate-Deck-November-2023-Final.pdf

Legal Disclaimer-


This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

COMPENSATION

Pursuant to an agreement between TD Media LLC and InMed Pharmaceuticals Inc., TD Media LLC has been hired for a period beginning on 04/21/2022 and ending on 06/10/2022 to publicly disseminate information about (INM:US) via digital communications. We have been paid one hundred seventy five thousand dollars USD. We own zero shares of (INM:US)

An owner of TD Media LLC owns and operates SWN Media LLC which owns and operates smallcapfirm . com (“SCF”), fierceinvestor . com (“FI”), and stockwirenews . com (“SWN”) and stockstreetwire .com (“SSW”). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media.

Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 4/21/22 and ending on 4/22/22 to publicly disseminate information about (INM) via Website, Email and SMS. SWN Media LLC was paid thirty thousand USD via bank wire transfer. We own zero shares of (INM).

Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 6/9/22 and ending on 6/10/22 to publicly disseminate information about (INM) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (INM).

Pursuant to an agreement between SWN Media LLC and North Equities Corp., StockStreetWire (SSW) has been hired for a period beginning on 11/15/22 and ending on 11/16/22 to publicly disseminate information about (INM) via Website, Email and SMS. SWN Media LLC was paid twenty-five thousand USD via bank wire transfer. We own zero shares of (INM).

Pursuant to an agreement between SWN Media LLC and InMed Pharmaceuticals Inc., StockStreetWire (SSW) has been hired for a period beginning on 3/15/23 and ending on 3/16/23 to publicly disseminate information about (INM) via Website, Email and SMS. SWN Media LLC was paid twenty-five thousand USD via bank wire transfer. We own zero shares of (INM).

Pursuant to an agreement between SWN Media LLC and InMed Pharmaceuticals Inc., StockStreetWire (SSW) has been hired for a period beginning on 10/23/23 and ending on 10/24/23 to publicly disseminate information about (INM) via Website, Email and SMS. SWN Media LLC was paid fifty thousand USD via bank wire transfer. We own zero shares of (INM). To date we have now been compensated a total of one hundred and fifty-seven thousand five hundred USD via bank wire transfer to disseminate information about (INM).